Bepotastine besilate nasal spray: Phase II data

Top-line data from a placebo-controlled, double-blinded U.S. Phase II trial in 600 patients with allergic rhinitis due to Mountain Cedar pollen showed that each of 3 dosages of bepotastine nasal spray twice daily met the primary endpoint of significantly reducing total nasal symptoms from baseline at day 14 vs. placebo. Furthermore, the nasal spray significantly reduced symptoms beginning on day 1. Two of the 3 doses also significantly improved Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores from baseline at day 14. Bepotastine was well tolerated. Ista said it plans to start a Phase II trial of bepotastine/steroid combination nasal spray by year end. ...